Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Knock at The Door
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(302)
•••
Comment by beenthereon May 19, 2023 5:18pm
139 Views
Post# 35457212

RE:RE:RE:RE:Knock at The Door

RE:RE:RE:RE:Knock at The DoorJd, hey old man, looking for some sympathy?

I'll give you some!

I'm not a rich man but I tied up a quarter of million in BTI!

To be honest you were the main reason I did!

For sure I wasn't aware all the underhanded stuff that was going on!

But not the least surprised!

I just finished 10 years of retirement and for 10 years I have done sfa!

Between BTI and PTK I am investment  broke!

What is done is done! It's my own fault but it's not just me.

I have a disabled wife 9 years younger than me and I  worry about the mess I created for her.

Long story short all water under the bridge.

If you are like me the way you think at say 40 is not the same as the way you think at 70+

Anyway in a long winded way I am saying I don't hold any thing against you!
We are still alive and I think that still counts for something! lol
As a good friend of my wife always says .....
.....Tomorrow will be a better day


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities